Skip to main content

Takeda says coronavirus treatment trial using recovered patients' blood could start in July

Takeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID-19 that is based on antibodies from recovered patients' blood, company executives said on Wednesday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.